Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 28, 2006Blood

Maintenance therapy with thalidomide improves survival in patients with multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

MAMichel AttalUniversité de ToursJHJean‐Luc HarousseauInstitut de Cancérologie de l'OuestSLSerge LeyvrazHumboldt-Universität zu Berlin

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Attal et al. (2006) studied this question.

synapsesocial.com/papers/6a7e7617cc2a0d08ea85652chttps://doi.org/10.1182/blood-2006-05-022962
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A Phase I/II National, Multi-Center, Open-Label Study of Bortezomib Plus Melphalan and Prednisone (V-MP) in Elderly Untreated Multiple Myeloma Patients.2004 · 39 citations
  2. 2Antitumor Activity of Thalidomide in Refractory Multiple Myeloma1999 · 2,605 citations
  3. 3Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma2006 · 743 citations
  4. 4Thalidomide Alone or With Dexamethasone for Previously Untreated Multiple Myeloma2002 · 569 citations
  5. 5Major Superiority of Melphalan - Prednisone (MP) + Thalidomide (THAL) over MP and Autologous Stem Cell Transplantation in the Treatment of Newly Diagnosed Elderly Patients with Multiple Myeloma.2005 · 65 citations